FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Phase 2

Completed

Conditions: Non-Neoplastic Hematologic and Lymphocytic Disorder

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Drug: Tacrolimus
Procedure: Umbilical Cord Blood Transplantation
Drug: Treosulfan

First Posted Date: 2009-06-12

Last Posted Date: 2021-08-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00919503

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

and more 3 locations

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage I Small Lymphocytic Lymphoma
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma
Stage II Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Vorinostat

First Posted Date: 2009-06-11

Last Posted Date: 2020-02-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00918723

Locations: 🇺🇸
Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Phase 2

Terminated

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine Phosphate
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation (TBI)
Other: Magnetic Affinity Cell Sorting
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation

First Posted Date: 2009-06-05

Last Posted Date: 2020-08-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00914940

Locations: 🇺🇸
Yale University School of Medicine/Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2010-11-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1452

Registration Number: NCT00897416

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Not Applicable

Completed

Conditions: Hot Flashes
Menopause
Vasomotor Symptoms

Interventions: Other: Placebo
Drug: Escitalopram

First Posted Date: 2009-05-07

Last Posted Date: 2013-03-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 205

Registration Number: NCT00894543

Locations: 🇺🇸
Northern California Kaiser, Division of Research, Oakland, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 2 locations

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Biological: ipilimumab
Drug: cyclophosphamide
Procedure: biopsy
Biological: aldesleukin
Other: immunohistochemistry staining method
Genetic: polymerase chain reaction
Other: immunoenzyme technique
Biological: therapeutic cytotoxic T lymphocytes

First Posted Date: 2009-03-30

Last Posted Date: 2017-04-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00871481

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Phase 2

Completed

Conditions: Intraocular Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Hairy Cell Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Childhood Diffuse Large Cell Lymphoma
Nodal Marginal Zone B-cell Lymphoma

Interventions: Biological: rituximab
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2009-03-23

Last Posted Date: 2018-01-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 63

Registration Number: NCT00867529

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Zanamivir or Oseltamivir
Drug: TCAD
Other: Open label treatment with TCAD

First Posted Date: 2009-03-23

Last Posted Date: 2013-08-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00867139

Locations: 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Chronic Myelogenous Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Myelodysplastic Syndromes

Interventions: Drug: treosulfan
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: methotrexate

First Posted Date: 2009-03-12

Last Posted Date: 2021-06-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 96

Registration Number: NCT00860574

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Radiation: Iodine I 131 Monoclonal Antibody BC8
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-03-12

Last Posted Date: 2020-04-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00860171

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy